Suman Kambhampati

Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial

Paul G. Richardson, Albert Oriol, Meral Beksaç et al. · The Lancet Oncology · 2019 · 375 citations · Full text

Hematological Malignancy, Medicine, Hematology +6

The First-in-Class Anti-CD47 Antibody Magrolimab (5F9) in Combination with Azacitidine Is Effective in MDS and AML Patients: Ongoing Phase 1b Results

David A. Sallman, Adam S. Asch, Monzr M. Al Malki et al. · Blood · 2019 · 216 citations

Inhibition of the TGF-β receptor I kinase promotes hematopoiesis in MDS

Li Zhou, Aaron Nguyen, Davendra Sohal et al. · Blood · 2008 · 177 citations · Full text

Rigosertib versus best supportive care for patients with high-risk myelodysplastic syndromes after failure of hypomethylating drugs (ONTIME): a randomised, controlled, phase 3 trial

Guillermo Garcia‐Manero, Pierre Fenaux, Aref Al‐Kali et al. · The Lancet Oncology · 2016 · 168 citations

Family Medicine, Bone Marrow Failure, Hematology +7

Prognostic value of end-of-induction PET response after first-line immunochemotherapy for follicular lymphoma (GALLIUM): secondary analysis of a randomised, phase 3 trial

Judith Trotman, Sally F. Barrington, David Belada et al. · The Lancet Oncology · 2018 · 152 citations · Full text

Lymphoid Neoplasia, End-of-induction Pet Response, Medicine +7